Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.